Zhiming Lin, Ph.D & MD
Title
Chief Physician, Graduate Supervisor, Department of Rheumatology and Immunology, 3rd Affiliated Hospital of Sun Yat-sen University
Research Interests
·Diagnosis and Therapy of Ankylosing Spondylitis and Spondyloarthritis
·Genetics of Ankylosing Spondylitis
·Study on the Pathogenesis of the Intestinal Microbiota and the Susceptible of HLA regionof Ankylosing Spondylitis and Systemic Lupus Erythematosus
His early research work focused on the clinical aspects of Ankylosing Spondylitis (AS) and Spondyloarthritis (SpA). In 2010, He was grated as “Guangdong Excellent Postgraduate of Guangdong Province”. In 2012, he completed the work as the first author, which screening for susceptibility genes of Ankylosing Spondylitis on population high-density genome-wide of in China, and he found two new susceptibility sites. His research has been published in Journals of The Top International Professional , Nature Genetics(IF: 41.307).
He has published papers more than 30 in SCI, including Nature Genetics, etc, which the first or contribute equally was total 21. In addition, he also has published the abstract almost 40 in the International Conference. Furthermore, he participated in “Oral Presentations” on International Conference of APLAR respectively in 2008, 2010, 2013, 2014.
Education and Experience
Training
·Sun Yat-sen university, undergraduate course (2000.9~2005.7)
·Sun Yat-sen University, doctorial course (2005.9~2010.7)
Residency
·3rd Affiliated Hospital of Sun Yat-sen University (2010.8~present)
Certifications
·Physician’s Qualification (2010.8)
·Attending doctor, Rheumatology and Immunology (2012.12)
·Associate Chief Physician, Rheumatology and Immunologyy (2014.12)
Chief Physician, Rheumatology and Immunology（2020.12）
Honors and Awards
·In 2012, he has got a grant from the National Natural Science Foundation for the youth NSFY of China, and In 2014, he also has got a grant from the Guangdong Natural Science Funds for Distinguished Young Scholar. etc.
·The Conference of APLAR in 2014, he honored “16 th APLAR Best Abstract Award”.
The first prize in China's State Natural Science Award & Second Prize in Natural Sciences Prize of Guangdong Province （Secondary co-author）in 2016
Publications
1.Lin ZM, et al.A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis.Nature Genets. 2012 Jan 4;44(1):73-7. （IF: 41.307）
2.Lin ZM, et al. Investigation and analysis on the delayed diagnosis in patients with ankylosing spondylitis in a Chinese population.Clin Exp Rheumatol. 2008 ;26(6):1163. （IF: 4.862）
3.Lin ZM, et al. Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients. Rheumatol Int.Rheumatol Int. 2011 Feb;31(2):233-8.（IF: 3.58）
4.Lin ZM, et al. Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept bytreatment. Rheumatol Int. 2010 Jan; 30(3): 317-323. （contribute equally）（IF: 3.58）
5,ERAP1 Is Associated with Ankylosing Spondylitis in Han Chinese. J Rheumatol. 2011 Feb;38(2):317-21. （contribute equally）（IF: 5.346）
6.The Ankylosing Spondylitis Disease Activity Score is a highly The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatology (Oxford). 2011 Aug;50(8):1466-72. （contribute equally）（IF: 7.046）
7.Lin ZM, et al. Evaluation of ASAS classification criteria for axial SpA in Chinese patients with chronic back pain: results of a two-year follow-up study. International Journal of Rheumatic Disease. 2014 Sep;17(7):782-9.（IF: 2.558）
8.Lin ZM, et al. Higher percentage of CD3+CD154+T lymphocytes predicts the efficacy of TNF-α inhibitors in active axial SpA patients. Inflammation. 2014 Dec;37(6):2056-61（IF: 4.657）
9.Lin ZM, et al. Predictive Factors of Clinical Response of Infliximab Therapy inActive Nonradiographic Axial Spondyloarthritis Patients. BioMed Research International. 2014 Dec （IF: 3.246）
10. Zhang YL, Lin ZM et al. A Genome-Wide SNP Linkage Analysis Suggests a Susceptibility Locus on 6p21 for Ankylosing Spondylitis and Inflammatory Back Pain Trait. Plos one. 2016 Dec 14;11(12):e0166888. (IF: 3.752）
11. Zhao MJ, Lin ZM et al. Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission:a three years'following-up study. Clinical rheumatology. 2018 Jan;37(1):87-92. (IF: 3.65）
12. Tong F, Lin ZM et al. An epidemiological study of the prevalence rate of inflammatory back pain and axial spondyloarthritis in a university in the south of China. Clinical rheumatology. 2018 Nov;37(11):3087-3091. (IF: 3.65）
13.Lv Q, Lin ZM et al. Using Mobile Apps for Health Management:A New Health Care Mode in China. JMIR mHealth and uHealth. 2019 Jun 3;7(6):e10299.（IF: 4.947）
14.Zhang X, Lin ZM et al. Prevalence of bone mineral density loss and potential risk factors for osteopenia and osteoporosis in rheumatic patients in China:logistic regression and random forest analysis. Annals of translational medicine. 2020 Mar;8(5):226. (IF: 3.616）
15.Feng JM, Lin ZM et al. "Genetic basis of relapsing polychondritis revealed by family-based whole-exome sequencing". International journal of rheumatic diseases. 2020 May;23(5):641-646.（IF: 2.55）
16. Hu ZR, Lin ZM et al. Prevalence and risk factors for bone loss in Southern Chinese with rheumatic diseases. BMC musculoskeletal disorders. 2020 Jun 30;21(1):416. (IF: 2.562）
17. Dai ZL, Lin ZM,et al. Treatment for Severe Lupus Nephritis: A Cost-Effectiveness Analysis in China. September 2021.Frontiers in Pharmacology. doi: 10.3389/fphar.2021.678301(IF: 5.988)
18. Du KQ. Lin ZM,et al. Cationic Nanomaterials for Autoimmune Diseases Therapy. January 2022.Frontiers in Pharmacology. doi: 10.3389/fphar.2021.762362. (IF: 5.988)
19. Ting Liu, Lin ZM, et al . Speciffc nanotherapeutics for highly efffcient diagnosis and treatment of systemic lupus erythematosus. 2021. Chemical Engineering Journal, https://doi.org/10.1016/j.cej.2021.133095 (IF: 16.744)
20. Du KQ, Lin ZM et al. Renal response and its predictive factors of lupus nephritis: a 2‑year real‑world study of 56 hospital‑based patients. 2022 June. Clinical Rheumatology. https://doi.org/10.1007/s10067-022-06258-0. (IF: 3.65）
21. Liu YH, Lin ZM, et al. Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review. September 2022 . Frontier in Cell and Developmental Biology. DOI 10.3389/fcell.2022.998328.(IF:6.081)
Research Projects
·Study on Genetic Molecule Precautionary of Ankylosing Spondylitis. This study was supported by Guangdong Natural Science Funds for Distinguished Young Scholar.(2015.1-2019.1)
·Study on Epidemiology and Susceptibility Genetic of Ankylosing Spondylitis. This study was supported by Pearl River Nova Program of Guangzhou.(2016.5-2019.4)
·Study on the Pathogenesis of the Intestinal Microbiota and the Susceptible of HLA regionof Ankylosing Spondylitis and Systemic Lupus Erythematosus. This study was supported by The Fundamental Research Funds for the Central Universities.(2016.1-2017.12)
Contact
3rd Affiliated Hospital of Sun Yat-sen University
600 Tianhe Road, Guangzhou, China
Tel : +8620-85253396
E-mail: lzm-zj99@163.com
